07:00 , Sep 28, 2015 |  BC Week In Review  |  Clinical News

ID93/GLA-SE: Phase IIa started

IDRI began a double-blind, dose-escalation, South African Phase IIa trial to evaluate intramuscular ID93 with GLA-SE at days 0 and 56 in about 60 adult patients who have successfully completed TB treatment with confirmed bacteriologic...
08:00 , Nov 13, 2014 |  BC Innovations  |  Cover Story

Boosting adjuvants

For all the talk of new vaccines, not much attention has been paid to the need for better adjuvants, which have remained stuck on alum-based products for decades. The NIH is committing up to $70...
07:00 , Jun 2, 2014 |  BC Week In Review  |  Company News

Japan BCG, Dainippon Sumitomo, Innovation Network Corp. deal

Innovation Network, vaccine company Japan BCG and Dainippon said they made a new joint investment of ¥845 million ($8.3 million) in Create Vaccine Co. Ltd. to fund preclinical development of mucosal tuberculosis (TB) vaccines. The...
07:00 , Apr 17, 2014 |  BC Innovations  |  Translation in Brief

Translational tidbits

AstraZeneca plc had a busy March, announcing five new public-private partnerships and the launch of its Open Innovation website to list additional partnership opportunities (see "Selected public-private partnerships for March 2014"). One of the public-private...
07:00 , Mar 24, 2014 |  BC Week In Review  |  Clinical News

AERAS-404: Phase II started

Aeras began a partially blind South African Phase II trial to evaluate AERAS-404 in 990 adolescents who have previously been vaccinated with Bacille Calmette-Guerin (BCG) as infants. Subjects will receive AERAS-404, placebo or revaccination with...
07:00 , Mar 24, 2014 |  BC Week In Review  |  Company News

Japan BCG, Astellas, Dainippon Sumitomo, Eisai, Merck KGaA, Aeras, Drugs for Neglected Diseases initiative (DNDi), Liverpool School of Tropical Medicine (LSTM),

The Global Health Innovative Technology (GHIT) awarded $12.5 million as part of the second round of awards to four partnerships developing drugs and vaccines to treat schistosomiasis, Chagas disease, parasitic roundworms and tuberculosis. The awards...
07:00 , Mar 17, 2014 |  BC Week In Review  |  Company News

Emergent BioSolutions, Valneva deal

Valneva transferred a license to develop vaccines for tuberculosis (TB) using its EB66 cell line to Emergent from the Oxford-Emergent Tuberculosis Consortium (OETC) Ltd. Valneva said financial terms of the deal were not disclosed but...
08:00 , Feb 3, 2014 |  BC Week In Review  |  Company News

Japan BCG, Dainippon Sumitomo, Aeras, National Institute of Biomedical Innovation deal

Create Vaccine Co. Ltd. - a JV between Dainippon and Japan BCG - and the institute announced they signed a formal partnership with the foundation to jointly develop mucosal tuberculosis vaccines based on the institute's...
08:00 , Dec 19, 2013 |  BC Innovations  |  Translation in Brief

Translational tidbits

Consorting with academia GlaxoSmithKline plc has set up an immuno-oncology consortium that invites academics from six cancer centers to view its nonpublic early pipeline programs and share ideas for new therapeutic candidates. The Oncology Clinical and Translational...
08:00 , Nov 18, 2013 |  BC Week In Review  |  Clinical News

AERAS-456: Phase I/IIa started

Not-for-profit Aeras and the Danish government institute said the South African Tuberculosis Vaccine Initiative (SATVI) began a 2-part, double-blind, South African Phase I/IIa trial to evaluate 3 doses of AERAS-456 containing 5, 15 or 50...